A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs

We present a sarcoma patient with a tumor reduction of more than 50% in lung metastasis after 2 single courses of the investigational medical product Lutathera ((177)Lu-DOTA0-Tyr3-octreotate). She was resistant to more than 6 lines of therapy including all the available active drugs in soft tissue s...

Descripción completa

Detalles Bibliográficos
Autores principales: Crespo-Jara, Aurora, González Manzano, Ramón, Lopera Sierra, Maribel, Redal Peña, María Carmen, Brugarolas Masllorens, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Interesting Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979627/
https://www.ncbi.nlm.nih.gov/pubmed/27355848
http://dx.doi.org/10.1097/RLU.0000000000001288
Descripción
Sumario:We present a sarcoma patient with a tumor reduction of more than 50% in lung metastasis after 2 single courses of the investigational medical product Lutathera ((177)Lu-DOTA0-Tyr3-octreotate). She was resistant to more than 6 lines of therapy including all the available active drugs in soft tissue sarcomas. The high expression of somatostatin receptors was shown by microarrays and Octreoscan. The overall duration of response exceeded 1 year.

Ejemplares similares